arrow_right
Clinical Validation
CLINICAL VALIDATION
STUDY RESULTS
For intermediate pre-test risk patients with an inconclusive bronchoscopy, Percepta GSC can down-classify the risk of primary lung cancer to low with a 91% NPV to help avoid additional invasive procedures or up-classify the risk to high with a 65% PPV to inform next intervention steps3.
LINK TO STUDY
CONTACT A REP TO ORDER VERACYTE TESTING
Veracyte representatives are happy to assist you and to discuss how to integrate our tests into your practice.
First Name*
Last Name*
Email*
Institution/Practice*
Zip Code*
Which Test Interests You?*
More About You*
Message
CONTACT REP
R E F E R E N C E S 
3. Bhorade S et al. Accuracy of the Next Generation Percepta Genomic Sequencing
Classifier (GSC) for the Diagnosis of Suspicious Indeterminant Pulmonary Nodules. Poster presented
at: Second Conference of the AABIP; August 15-17, 2019; Denver, CO.
© 2021 Veracyte, Inc. All rights reserved.